Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Sells $205,607.81 in Stock

Posted by Geri Gentry on Sep 9th, 2026

Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Free Report) major shareholder Bioventures 2018 L.P. Mpm sold 28,837 shares of Entrada Therapeutics stock in a transaction that occurred on Wednesday, September 9th. The stock was sold at an average price of $7.13, for a total transaction of $205,607.81. Following the completion of the sale, the insider directly owned 3,885,115 shares of the company’s stock, valued at approximately $27,700,869.95. This trade represents a 0.74% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Bioventures 2018 L.P. Mpm also recently made the following trade(s):

On Tuesday, September 8th, Bioventures 2018 L.P. Mpm sold 192,500 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.41, for a total value of $1,426,425.00.
On Friday, September 4th, Bioventures 2018 L.P. Mpm sold 38,500 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.11, for a total value of $273,735.00.
On Thursday, September 3rd, Bioventures 2018 L.P. Mpm sold 32,263 shares of Entrada Therapeutics stock. The shares were sold at an average price of $7.17, for a total value of $231,325.71.
On Wednesday, September 2nd, Bioventures 2018 L.P. Mpm sold 25,131 shares of Entrada Therapeutics stock. The shares were sold at an average price of $7.19, for a total value of $180,691.89.
On Tuesday, September 1st, Bioventures 2018 L.P. Mpm sold 29,088 shares of Entrada Therapeutics stock. The shares were sold at an average price of $7.06, for a total value of $205,361.28.
On Monday, August 31st, Bioventures 2018 L.P. Mpm sold 44,259 shares of Entrada Therapeutics stock. The stock was sold at an average price of $6.99, for a total value of $309,370.41.
On Friday, August 28th, Bioventures 2018 L.P. Mpm sold 3,733 shares of Entrada Therapeutics stock. The shares were sold at an average price of $7.01, for a total value of $26,168.33.
On Thursday, August 27th, Bioventures 2018 L.P. Mpm sold 38,922 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.20, for a total transaction of $280,238.40.

Entrada Therapeutics Trading Down 5.5%

NASDAQ TRDA traded down $0.41 during trading hours on Wednesday, hitting $7.11. 381,776 shares of the company’s stock traded hands, compared to its average volume of 247,577. The business’s fifty day moving average price is $7.05 and its two-hundred day moving average price is $9.09. The firm has a market capitalization of $276.86 million, a P/E ratio of -1.80 and a beta of -0.25. Entrada Therapeutics, Inc. has a 52 week low of $5.02 and a 52 week high of $16.45.

Entrada Therapeutics (NASDAQ:TRDA – Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.04). The business had revenue of $0.90 million for the quarter, compared to the consensus estimate of $2.32 million. Entrada Therapeutics had a negative net margin of 3,537.73% and a negative return on equity of 57.61%. On average, sell-side analysts expect that Entrada Therapeutics, Inc. will post -4.03 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on TRDA shares. Wall Street Zen upgraded Entrada Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Weiss Ratings raised Entrada Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, August 31st. Roth Capital reiterated a “buy” rating and set a $11.00 target price on shares of Entrada Therapeutics in a research report on Wednesday, August 12th. Finally, Guggenheim decreased their target price on Entrada Therapeutics from $20.00 to $17.00 and set a “buy” rating on the stock in a research note on Monday, June 8th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $17.75.

Read Our Latest Stock Analysis on TRDA

Institutional Trading of Entrada Therapeutics

Large investors have recently made changes to their positions in the business. 5AM Venture Management LLC bought a new position in shares of Entrada Therapeutics in the 2nd quarter valued at about $29,854,949. BlackRock Inc. bought a new stake in Entrada Therapeutics during the second quarter worth approximately $19,013,000. Millennium Management LLC raised its position in Entrada Therapeutics by 391.2% during the third quarter. Millennium Management LLC now owns 836,609 shares of the company’s stock valued at $4,852,000 after purchasing an additional 666,287 shares during the period. Nantahala Capital Management LLC bought a new stake in shares of Entrada Therapeutics in the 2nd quarter valued at approximately $2,212,232. Finally, Citadel Advisors LLC boosted its holdings in shares of Entrada Therapeutics by 234.5% in the 3rd quarter. Citadel Advisors LLC now owns 335,741 shares of the company’s stock worth $1,947,000 after purchasing an additional 235,384 shares during the period. 86.39% of the stock is currently owned by institutional investors.

About Entrada Therapeutics

(Get Free Report)

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.